Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -227.85% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -5.54
Flat results in Jun 26
Stock is technically in a Mildly Bearish range
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 40 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
0.27
-32.27%
1.04
Total Returns (Price + Dividend) 
Vista Pharma. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Vista Pharmaceuticals Ltd is Rated Strong Sell
Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Vista Pharmaceuticals Ltd is Rated Strong Sell
Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Vista Pharmaceuticals Ltd Falls to 52-Week Low of Rs 5.5 as Sell-Off Deepens
For the second consecutive session, Vista Pharmaceuticals Ltd has seen its share price decline, hitting a fresh 52-week low of Rs 5.5 on 8 Sep 2026. This latest drop extends the stock’s downward trajectory, which has now resulted in a 5.41% loss over just two days, underscoring persistent selling pressure amid broader market weakness.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
12-Sep-2026 | Source : BSEResignation of Company Secretary & Compliance Officer
Board Meeting Outcome for Results For The Quarter Ended 30.06.2026
14-Aug-2026 | Source : BSEResults for the quarter ended 30.06.2026
Results For The Quarter Ended 30.06.2026
14-Aug-2026 | Source : BSEResults for the quarter ended 30.06.2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 4 Schemes (0.02%)
Held by 0 FIIs
Vista Pharmaceuticals Inc (10.69%)
Murali Meraga (14.62%)
33.63%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 0.00% vs -100.00% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 83.11% vs -152.59% in Mar 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -30.54% vs -21.28% in Sep 2024
Growth in half year ended Sep 2025 is -112.02% vs 38.38% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -21.17% vs -4.20% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -96.83% vs 31.52% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -46.38% vs -2.14% in Mar 2025
YoY Growth in year ended Mar 2026 is -159.35% vs -3.10% in Mar 2025